NVCT today
$20.23-$0.77 (-3.67%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourSymmetric Triangle
15 minBearish
5 minStrong Bearish
Daily trend turns down below $9.22
Key levels
Resistance$25.19
Resistance$21.72
Support$19.55
Support$17.69
Latest news & SEC filings
EarningsNuvectis Pharma Posts Q3 2026 Results
EarningsNuvectis Pharma holds Q3 2026 earnings call
EarningsNuvectis Pharma reports Q3 EPS of $(1.02), missing $(0.24) estimate
SEC FilingNuvectis Pharma, Inc. filed a report on a major company event (Form 8-K)
All NVCT news →About Nuvectis Pharma
Nuvectis Pharma is a clinical-stage biopharmaceutical company developing precision medicines for cancer. Its lead product candidate, NXP900, is an oral small molecule inhibitor of the SRC and YES1 kinases, licensed from the University of Edinburgh, and is being studied in a Phase 1 trial for advanced solid tumors. The company has no approved products and operates in the United States.
Based on the company's 10-K filed Feb 11, 2026.
Nasdaq · Healthcare
Nuvectis Pharma, Inc. (NVCT)
What Is the Price Target for NVCT?
SEPT Low Target
$13.00
SEPT Mid Target
$26.00
SEPT High Target
$39.00
Analyst Consensus
$26.00
Is NVCT a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NVCT.
Start Free Trial →Is NVCT Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/B, Analyst Consensus
Fair Value
$22.12
7
Moat Score
NONE
4/9
Piotroski Score
11.6
Altman Z-Score
What Is Smart Money Doing with NVCT?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Hoberman Kenneth | director | Buy | 35,000 | - | Jun 11, 2026 |
| Oliviero James F III | director | Buy | 35,000 | - | Jun 11, 2026 |
| Sanchez Juan | director | Buy | 35,000 | - | Jun 11, 2026 |
| Kaplan Matthew L. | director | Buy | 35,000 | - | Jun 11, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →NVCT Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-18.92%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for NVCT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for NVCT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:26:18 | $21.00 | 2,057 | $$43K | SELL |
| 14:43:37 | $21.78 | 5,000 | $$109K | BUY |
| 21:00:23 | $21.08 | 1,012 | $$21K | BUY |
| 20:41:08 | $20.94 | 1,291 | $$27K | SELL |
| 15:16:16 | $21.30 | 6,000 | $$128K | BUY |
5 dark pool trades shown · $$328K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Nuvectis Pharma, Inc. (NVCT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (4 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →NVCT — frequently asked questions
What is NVCT stock price today?
Nuvectis Pharma, Inc. (NVCT) is at $20.23, down 3.67% (-$0.77) at the Nov 12, 2026 close.
Why is NVCT stock moving today?
Latest NVCT news — Nov 4, 2026: Nuvectis Pharma Posts Q3 2026 Results · Nov 4, 2026: Nuvectis Pharma holds Q3 2026 earnings call
Why did NVCT stock move on Nov 4, 2026?
Nuvectis Pharma shares fell 3.25% to close at $18.46 after the company reported third-quarter 2026 results that included a loss per share of $(1.02), missing the $(0.24) estimate. The stock traded in a wide range on the day, hitting a high of $20.55 and a low of $17.10 on volume of 324,717 shares.
What is the NVCT price target?
The average analyst price target for NVCT is $26.00, ranging from $13 to $39, based on 2 analysts.
What do analysts rate NVCT?
Analyst ratings for NVCT: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
Did NVCT beat earnings?
NVCT last reported on Nov 4, 2026: EPS -$1.02 vs -$0.24 expected — a miss of 325.0%.
Does NVCT pay a dividend?
NVCT does not currently pay a dividend.
What are NVCT support and resistance levels?
Support: $19.55, $17.69, $13.34. Resistance: $21.72, $25.19, $29.27.
What are insiders doing with NVCT?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on NVCT?
Nov 4, 2026: Nuvectis Pharma Posts Q3 2026 Results · Nov 4, 2026: Nuvectis Pharma holds Q3 2026 earnings call · Nov 4, 2026: Nuvectis Pharma reports Q3 EPS of $(1.02), missing $(0.24) estimate